Global Antibody Contract Manufacturing Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

Spread the love

Overview and Scope

Antibody contract manufacturing refers to outsourcing the production and manufacturing of antibodies to specialized contract manufacturing organizations (CMOs). These CMOs are equipped with the expertise, infrastructure, and resources necessary to manufacture antibodies on behalf of pharmaceutical and biotechnology companies.

Sizing and Forecast

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $12.84 billion in 2023 to $14.71 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $25.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (cdmo).

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Segmentation & Regional Insights

The antibody contract manufacturing market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users

North America was the largest region in the antibody contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp

Major Driver Impacting Market Growth

The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing market.

Key Industry Players

Major companies operating in the antibody contract manufacturing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Pierre Fabre Group, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

The antibody contract manufacturing market report table of contents includes:

1. Executive Summary

2. Antibody Contract Manufacturing Market Characteristics

3. Antibody Contract Manufacturing Market Trends And Strategies

4. Antibody Contract Manufacturing Market – Macro Economic Scenario

5. Global Antibody Contract Manufacturing Market Size and Growth

32. Global Antibody Contract Manufacturing Market Competitive Benchmarking

33. Global Antibody Contract Manufacturing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibody Contract Manufacturing Market

35. Antibody Contract Manufacturing Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →